Taxus Cardium Pharmaceuticals Stock Probability Of Bankruptcy
| CRXMDelisted Stock | USD 0.0001 0.00 0.00% |
Taxus |
Taxus Cardium Pharmaceuticals Company odds of distress Analysis
Taxus Cardium's Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
More About Probability Of Bankruptcy | All Equity Analysis
Probability Of Bankruptcy | = | Normalized | | Z-Score |
Current Taxus Cardium Probability Of Bankruptcy | Over 100% |
Most of Taxus Cardium's fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Taxus Cardium Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Our calculation of Taxus Cardium probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting Taxus Cardium odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of Taxus Cardium Pharmaceuticals financial health.
The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
CompetitionBased on the latest financial disclosure, Taxus Cardium Pharmaceuticals has a Probability Of Bankruptcy of 100%. This is 131.0% higher than that of the Biotechnology sector and 82.35% higher than that of the Health Care industry. The probability of bankruptcy for all United States stocks is 151.07% lower than that of the firm.
Taxus Probability Of Bankruptcy Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Taxus Cardium's direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Taxus Cardium could also be used in its relative valuation, which is a method of valuing Taxus Cardium by comparing valuation metrics of similar companies.Taxus Cardium is currently under evaluation in probability of bankruptcy category among its peers.
Taxus Fundamentals
| Return On Asset | -2.62 | |||
| Current Valuation | 881.11 K | |||
| Shares Outstanding | 64.93 M | |||
| Shares Owned By Insiders | 0.21 % | |||
| Number Of Shares Shorted | 150.25 K | |||
| Price To Book | 3.36 X | |||
| Price To Sales | 137.13 X | |||
| EBITDA | (458.68 K) | |||
| Net Income | (517.9 K) | |||
| Cash And Equivalents | 386.03 K | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 1.26 M | |||
| Debt To Equity | (1.01) % | |||
| Current Ratio | 0.08 X | |||
| Book Value Per Share | (0.1) X | |||
| Cash Flow From Operations | (1.13 M) | |||
| Short Ratio | 1.03 X | |||
| Earnings Per Share | (0.02) X | |||
| Target Price | 2.0 | |||
| Beta | -48.52 | |||
| Market Capitalization | 64 | |||
| Total Asset | 566.98 K | |||
| Retained Earnings | (114.05 M) | |||
| Working Capital | (3.8 M) | |||
| Current Asset | 30.78 K | |||
| Current Liabilities | 3.83 M | |||
| Net Asset | 566.98 K |
About Taxus Cardium Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Taxus Cardium Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Taxus Cardium using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Taxus Cardium Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Other Consideration for investing in Taxus Pink Sheet
If you are still planning to invest in Taxus Cardium Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Taxus Cardium's history and understand the potential risks before investing.
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins |